930630ee-1c36-4567-aeff-042eef1654e6
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 65
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.570
- MYC_TARGETS_V1+0.530
- OXIDATIVE_PHOSPHORYLATION+0.510
- MYC_TARGETS_V2+0.490
- G2M_CHECKPOINT+0.480
- MTORC1_SIGNALING+0.460
- PROTEIN_SECRETION+0.380
- CHOLESTEROL_HOMEOSTASIS+0.370
- UNFOLDED_PROTEIN_RESPONSE+0.350
- GLYCOLYSIS+0.340
Top 10 suppressed
- MYOGENESIS-0.340
- HEDGEHOG_SIGNALING-0.330
- WNT_BETA_CATENIN_SIGNALING-0.290
- APICAL_JUNCTION-0.170
- PANCREAS_BETA_CELLS-0.150
- ESTROGEN_RESPONSE_EARLY-0.130
- P53_PATHWAY-0.120
- COAGULATION-0.080
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.060
- MITOTIC_SPINDLE-0.060
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_5CTVXVRX | high-grade glioma | — | 0.874 |
| 2 | feccc57b-a987-4dd7-babf-1a8982bd64cc | — | — | 0.871 |
| 3 | 77984740-019e-482f-822a-25a74ec2cc32 | — | — | 0.869 |
| 4 | SRR6013495 | — | cohortA1 | 0.865 |
| 5 | MNG767 | — | — | 0.860 |
| 6 | 8824c0fd-764e-4525-952b-f25efa742772 | — | — | 0.854 |
| 7 | SRR11296852 | — | — | 0.846 |
| 8 | SRR35579824 | — | E | 0.846 |
| 9 | c7aea5a2-5772-4475-8ca6-326193eeb69e | — | — | 0.841 |
| 10 | SRR12696741 | — | — | 0.839 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 32 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.570 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.530 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.510 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.490 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.480 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.460 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.380 | Remibrutinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.370 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.350 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.340 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.300 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.300 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.290 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.250 | Inavolisib | — uncovered |
| PEROXISOME | 0.250 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.240 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.240 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.230 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.220 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.220 | Inavolisib | — uncovered |